Characteristics | Total AS patients (n = 65) | Group A (n = 39) | Group B (n = 26) | P value |
---|---|---|---|---|
BMI | 25.8 ± 4.7 (16.6–39.5) | 25.9 ± 4.5 (17.7–38.9) | 25.6 ± 5.0 (16.6–39.5) | 0.851 |
Male gender, n (%) | 56 (86.2%) | 34 (87.2%) | 22 (84.6%) | 1.000 |
Age at onset (years) | 23.3 ± 6.0 (14–39) | 25.0 ± 5.9 (15–39) | 20.9 ± 5.5 (14–34) | 0.006 |
Age at outpatient visit (years) | 33.3 ± 9.1 (17–54) | 32.7 ± 7.5 (18–49) | 34.2 ± 11.1 (17–54) | 0.995 |
Duration of AS (years) | 10.2 ± 9.4 (0–37) | 8.0 ± 6.6 (0–24) | 13.6 ± 11.8 (0–37) | 0.131 |
Diagnosis delay (years) | 5.6 ± 7.3 (0–33) | 4.6 ± 6.2 (0–33) | 7.1 ± 8.5 (0–27) | 0.556 |
EAMs, n (%) | ||||
 Uveitis | 4 (6.2%) | 2 (5.1%) | 2 (7.7%) | 1000 |
 IBD | 4 (6.2%) | 2 (5.1%) | 2 (7.7%) | 1.000 |
 Family history, n (%) | 14 (21.5%) | 8 (20.5%) | 6 (23.1%) | 0.805 |
 HLA-B27 positivity, n (%) | 61 (93.8%) | 37 (94.9%) | 24 (92.3%) | 1.000 |
 Current use of NSAIDs, n (%) | 43 (66.2%) | 28 (71.8%) | 15 (57.7%) | 0.239 |
 Current use of DMARDs, n (%) | 35 (53.8%) | 24 (61.5%) | 11 (42.3%) | 0.128 |
 ESR (mm) | 31.8 ± 20.3 (2–93) | 27.9 ± 20.1 (2–91) | 37.7 ± 19.6 (10–93) | 0.020 |
 CRP (mg/L) | 26.8 ± 27.1 (1.9–133.0) | 22.8 ± 26.6 (1.9–133.0) | 32.7 ± 27.1 (2.2–107.0) | 0.035 |
 hsCRP (mg/L) | 25.5 ± 28.7 (0.1–137.4) | 22.3 ± 27.7 (0.1–131.5) | 30.4 ± 30.0 (0.8–137.4) | 0.111 |
 BASDAI | 3.8 ± 2.1 (0.4–8.4) | 3.0 ± 1.9 (0.4–7.8) | 4.8 ± 1.9 (0.4–8.4) | 0.001 |
 BASFI | 2.1 ± 1.6 (0.2–6.3) | 1.5 ± 1.0 (0.2–4.4) | 3.2 ± 1.7 (0.5–6.3) | < 0.001 |
 SF-12 PCS | 37.5 ± 12.0 (16.5–58.4) | 40.5 ± 11.8 (19.6–58.4) | 33.1 ± 11.1 (16.5–55.1) | 0.014 |
 SF-12 MCS | 39.3 ± 11.6 (17.1–57.8) | 42.4 ± 11.3 (22.4–57.8) | 34.9 ± 10.8 (17.1–54.3) | 0.009 |
 ASQOL | 6.4 ± 4.5 (0–17) | 5.0 ± 4.1 (0–14) | 8.4 ± 4.3 (2–17) | 0.002 |
 HHS | 75.7 ± 19.8 (24–100) | 87.5 ± 9.6 (65–100) | 58.1 ± 18.1 (24–95) | < 0.001 |
 BASRI-Hip | 1.9 ± 1.4 (0–4) | 0.9 ± 0.8 (0–2) | 3.3 ± 0.5 (3–4) | < 0.001 |